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Systemic juvenile idiopathic arthritis (sJIA) is the form of childhood arthritis whose
treatment is most challenging. The demonstration of the prominent involvement of
interleukin (IL)-1 in disease pathogenesis has provided the rationale for the treatment with
biologicmedications that antagonize this cytokine. The three IL-1 blockers that have been
tested so far (anakinra, canakinumab, and rilonacept) have all been proven effective and
safe, although only canakinumab is currently approved for use in sJIA. The studies on IL-1
inhibition in sJIA published in the past few years suggest that children with fewer affected
joints, higher neutrophil count, younger age at disease onset, shorter disease duration,
or, possibly, higher ferritin level may respond better to anti-IL-1 treatment. In addition, it
has been postulated that use of IL-1 blockade as first-line therapy may take advantage
of a “window of opportunity,” in which disease pathophysiology can be altered to prevent
the occurrence of chronic arthritis. In this review, we analyze the published literature on
IL-1 inhibitors in sJIA and discuss the rationale underlying the use of these medications,
the results of therapeutic studies, and the controversial issues.
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INTRODUCTION
Systemic juvenile idiopathic arthritis (sJIA) is the most severe form of childhood arthritis and the
most difficult to treat. Until recently, sJIA was considered a therapeutic orphan, since the most
effective treatment was corticosteroids, whose long-term administration is associated with a wide
range of side effects, including an increased risk of vertebral fractures, cataracts, growth retardation,
and susceptibility to infection. Traditional disease-modifying anti-rheumatic drugs (DMARDs),
such as methotrexate, have limited efficacy for the joint disease and virtually no impact on the
systemic features. Poor responses have also been reported with the newer anti-tumor necrosis
factor (TNF) agents (Quartier et al., 2003; Horneff et al., 2004; Kimura et al., 2005; Solari et al.,
2013), although these medications may be effective in the later afebrile disease phase, characterized
by chronic arthritis (Lovell et al., 2008; Giannini et al., 2009). Recently, anti-TNF therapy was
found to restore normal levels of vasculoprotective and proangiogenic endothelial progenitor cells
in children with JIA (Martini et al., 2015). Several experimental studies have suggested a major
pathogenetic role for cytokines such as interleukin (IL)-6 (de Benedetti and Martini, 2005) and,
more recently, IL-1 (Pascual et al., 2005). These findings have opened the way to the successful
treatment of sJIA with biologic agents that antagonize selectively these cytokines.
In the present review, we provide a brief overview of the main clinical features of sJIA and
summarize the recent advances in therapy with IL-1 inhibitors.
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CLINICAL CHARACTERISTICS OF sJIA
sJIA accounts for 5–15% of all children with chronic arthritis
in Europe and North America and is rather distinct from
the other forms of JIA, owing to the association of arthritis
with a severe systemic illness (Martini, 2012a; De Benedetti
and Schneider, 2016). It is considered the childhood-onset
equivalent of adult-onset Still’s disease. Children with sJIA
typically present with a quotidian, high-spiking fever, often
accompanied by an erythematous, salmon pink, macular rash,
which tends to be migratory and is strikingly evanescent
(Figure 1). Myalgias and abdominal pain may be intense
during fever peaks. Other systemic manifestations include
diffuse lymphoadenopathy, hepatosplenomegaly, and serositis,
especially pleuritis and pericarditis. Arthritis is more often
symmetrical and polyarticular, but may be absent at onset and
develop during the disease course weeks, months, or, rarely,
years after the occurrence of extra-articular symptoms. At disease
presentation, particularly when arthritis is not yet present,
children often require an accurate diagnostic work-up to exclude
other potential diagnoses, such as infections and malignancy.
Characteristic laboratory features include anemia (usually
hypochromic and microcytic), leukocytosis, thrombocytosis,
elevated immunoglobulins, increased erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP), and hypoalbuminemia.
The International League for Associations of Rheumatology
(ILAR) criteria for the classification of sJIA are shown in Table 1.
It has recently been argued that there are patients not
classifiable as sJIA by current criteria who present with the same
systemic features seen in classic sJIA, but never develop arthritis
(Martini, 2012a). The similarity of clinical manifestations suggest
that their illness is closely related to sJIA, despite the absence
of arthritis. This subgroup of patients, which nowadays lacks a
taxonomic designation, would meet the criteria for adult-onset
FIGURE 1 | Salmon-macular rash in systemic juvenile idiopathic
arthritis.
Still’s disease, which do not require the presence of arthritis for
diagnosis (Yamaguchi et al., 1992). These considerations have
led to propose to include these patients in the sJIA category,
and to rename sJIA as Still’s disease in order to harmonize
the terminology with that of the adult counterpart (Martini,
2012b). A recent analysis of initial clinical features of 136 children
with sJIA through a Web-based registry has shown that the
ILAR criteria identified only 30% of sJIA patients at disease
presentation (Behrens et al., 2008).
The course and prognosis of sJIA are variable (Martini, 2012a;
De Benedetti and Schneider, 2016). Around 40% of patients
have a good long-term outcome, with a monocyclic course that
enters a permanent remission with time. A small proportion
of patients have an intermittent course, with relapses followed
by periods of quiescence. In the remaining half of the patients,
the disease pursues a more severe, persistent disease course.
Among this unremitting subset, the sickest children have ongoing
systemic symptoms, early destructive polyarthritis (Figure 2),
growth failure, and are exposed to the serious side effects of
corticosteroids. This particular disease phenotype represents the
most disabling of all the different forms of JIA.
Children with sJIA are uniquely susceptible to develop a
potentially fatal complication known as macrophage activation
syndrome (MAS). MAS is characterized by an overwhelming
inflammatory reaction due to an uncontrolled and dysfunctional
immune response involving the continued activation and
expansion of T lymphocytes and macrophages, with resultant
massive hypersecretion of proinflammatory cytokines (Ravelli
et al., 2012; Grom et al., 2016). Distinctive clinical features
of MAS are high, non-remitting fever, hepatosplenomegaly,
generalized lymphadenopathy, central nervous system
dysfunction, hemorrhagic manifestations, and, in its most
extreme forms, multiorgan failure. Characteristic laboratory
abnormalities include pancytopenia, increased levels of ferritin,
liver enzymes, lactate dehydrogenase, triglycerides, D-dimers,
and soluble IL-2 receptor a (also known as soluble CD25), and
decreased fibrinogen levels. A characteristic histopathologic
feature of MAS is the accumulation of well-differentiated
TABLE 1 | ILAR criteria for sJIA.
Arthritis with, or preceded by, daily fever of at least 2 weeks’ duration that is
documented to be quotidian for at least 3 days, and accompanied by one or
more of the following:
(1) evanescent, non-fixed, erythematous rash
(2) generalized lymphadenopathy
(3) hepatomegaly or splenomegaly
(4) pericarditis, pleuritis and/or peritonitis
Exclusion criteria
- Psoriasis or a history of psoriasis in patient or first-degree relative
- Arthritis in HLA-B27–positive male >6 years of age
- HLA-B27 associated diseases such as ankylosing spondylitis,
enthesitis-related arthritis, sacroiliitis with inflammatory bowel disease, reactive
arthritis, or acute anterior uveitis; or history of these in a first-degree relative
- Positive rheumatoid factor test on two occasions ≥ 3 months apart
Adapted from Petty et al. (2004).
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FIGURE 2 | X-ray showing advanced destructive changes in the hips of
a systemic JIA patient.
macrophages exhibiting hemophagocytic activity in bone
marrow biopsy specimens or aspirates (Figure 3; Ravelli, 2002).
Although ∼10% of sJIA patients develop overt MAS, up to 30%
of children have evidence of subclinical MAS (Behrens et al.,
2007; Bleesing et al., 2007). MAS can result in progressive multi-
organ failure and eventually a fatal outcome if unrecognized.
Recent studies indicate a mortality rate of 8% (Minoia et al.,
2014, 2015). In 2016, classification criteria for MAS complicating
sJIA have been published (Table 2) (Ravelli et al., 2015, 2016).
INTERLEUKIN-1 INHIBITORS IN THE
MANAGEMENT OF sJIA
Anakinra
The first observation of successful treatment of sJIA with IL-1
inhibition dates back to 2004, when a remarkable response to
the recombinant interleukin (IL)-1 receptor antagonist anakinra
in two patients with severe and refractory disease manifestations
was described (Verbsky and White, 2004).
In a landmark study published in 2005, Pascual et al. (2005)
reported that the administration of anakinra to 9 children
with active sJIA refractory to other therapies led to striking
improvement in clinical symptoms and inflammatory markers.
Seven patients achieved complete remission and the other 2
patients had a partial response. The rationale for the treatment
was provided by the demonstration that patients’ serum induced
the transcription of innate immunity genes, included those of IL-
1α and IL-1β, in healthy peripheral-bloodmononuclear cells, and
that patients’ peripheral-blood mononuclear cells produced an
excess of IL-1β upon activation.
A less impressive effectiveness was seen in a French
multicenter, randomized, double-blind, placebo-controlled trial
(ANAJIS trial), whose primary outcome was the achievement of
an American College of Rheumatology Pediatric (ACR Pedi) 30
response at 1 month. At treatment endpoint, 8 of 12 patients
(67%) in the anakinra group and only 1 of 12 patients (8%) in
the placebo group were responders (p = 0.003). However, no
FIGURE 3 | Bone marrow specimen showing macrophage
hemophagocytosis in a patient with systemic arthritis and
macrophage activation syndrome.
TABLE 2 | 2006 classification criteria of MAS.
A febrile patient with known or suspected systemic juvenile idiopathic
arthritis is classified as having macrophage activation syndrome if the
following criteria are met:
Ferritin > 684 ng/ml and any two of the following:
Platelet count ≤ 181 × 109/liter
Aspartate aminotransferase > 48 units/liter
Triglycerides > 156mg/dl
Fibrinogen ≤ 360mg/dl
Adapted from Ravelli et al. (2015, 2016).
patient in both groups achieved a more robust improvement
(i.e., a modified ACR Pedi 100 response). Furthermore, loss of
response was observed in most patients over time. The authors
attributed the frequent lack of sustained efficacy to the presence
of severe polyarthritis and the absence of fever in most patients at
enrolment, to the possible insufficient dosage in younger patients,
and to the study design, which precluded the concomitant use of
DMARDs and allowed early tapering of corticosteroids. Notably,
a de novo type I interferon signature, which is not a feature of
untreated sJIA, was induced in the majority of anakinra-treated
patients, regardless of clinical response (Quartier et al., 2011).
That anakinra could be less effective on arthritis symptoms
than on systemic and laboratory features of inflammation was
highlighted in a retrospective study by Gattorno et al. (2008).
By examining the pattern of response to anakinra in 22 children
with sJIA, they identified two groups of patients: one group
exhibited a dramatic response, with rapid improvement of
arthritis and normalization of the CRP within the first week
of treatment; the other group had no response or experienced
only transient improvement of joint disease and CRP. The
only difference between responders and non-responders or
incomplete responders was a lesser extension of arthritis and
an increased absolute neutrophil count in the former group. In
vitro secretion of IL-1β and IL-18 by patient monocytes was not
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increased and was independent of both treatment outcome and
disease activity. Other case series published around the same time
also showed remarkable benefit among many, but not all, users of
anakinra (Lequerré et al., 2008; Ohlsson et al., 2008; Zeft et al.,
2009).
Recent observations suggest that initiation of anakinra early
in the disease course may improve outcome. A multicenter
retrospective cohort study of 46 patients who had received
anakinra as part of initial corticosteroid-sparing regimen
showed that around 60%, including 8 of 10 receiving anakinra
monotherapy, attained a complete response without escalation of
therapy. Almost all patients had rapid improvements in fever and
rash, whereas a slower response of arthritis to treatment was seen,
with persistently active synovitis in 39% of patients at 1 month,
27% of patients at 3 months, and 15% of patients at 6 months.
Inflammatory markers normalized in most patients within 1
month. Evidence that early intervention with anakinra could
prevent the development of persistent synovitis was obtained
for 91% of 35 patients followed up for at least 6 months.
Disease characteristics and treatment were similar in patients
with partial or absent response and patients with complete
response, except that that the former patients were markedly
younger at disease onset (median age 5.2 years vs. 10.2 years;
P = 0.004). Notably, however, the median peak ferritin level
was higher in complete responders than in partial or non-
responders (3008 vs. 1329 ng/ml). Although the difference was
not significant, perhaps owing to the small size of the study
population, this observation suggests that patients with more
prominent activation of the monocyte/macrophage system are
more responsive to IL-1 inhibition (Nigrovic et al., 2011).
Vastert et al. (2014) conducted the first prospective study
of the use of an IL-1 antagonist as first-line therapy in sJIA.
They started anakinra in 20 patients with new-onset sJIA who
were corticosteroid-naïve. At 3 months, 85% of patients achieved
an adapted ACR Pedi 90 response or had inactive disease;
75% of patients achieved this response while receiving anakinra
monotherapy. In the majority of responding patients (73%),
treatment could be stopped within 1 year, with remission being
preserved during follow-up. However, in around one third of
patients, concomitant therapy was required for maintenance of
clinical response. IL-18 as well as the myeloid-related proteins
(MRP) S100A12 and S100A8/9 were found to be potential
biomarkers for guiding the strategy of stopping treatment with
IL-1 inhibitors.
A recent single-center experience with anakinra therapy in 25
patients with sJIA showed that 56% of patients attained inactive
disease. The only baseline variable significantly associated with
response was the time interval disease onset and treatment start,
with earlier treatment being associated with better outcome.
Oncemore, however, themedian ferritin level tended to be higher
in patients who reached inactive disease than in those who did
not (1506 vs. 360 ng/ml). Importantly, the comparison of the dose
administered with the ideal dose of anakinra in each individual
patient did not show any relation with therapeutic response
(Pardeo et al., 2015).
In spite of the demonstrations of its effectiveness, anakinra is
not currently registered for the treatment of sJIA.
Canakinumab
A preliminary phase II, multicenter, open-label study evaluated
dosing, efficacy, and safety of the fully human anti-IL-1β antibody
canakinumab in 23 children with sJIA and active systemic
features. This analysis showed that the administration of 4
mg/kg was associated with rapid and sustained improvement
in clinical response and enabled reduction or discontinuation
of corticosteroids. In keeping with the findings of the
aforementioned study by Gattorno et al. (2008), responders to
canakinumab had fewer active joints and a higher white blood
cell count at baseline than did non-responders (Ruperto et al.,
2010).
The results of this pilot study provided the basis for
performing two double-blind placebo-controlled trials of
canakinumab in a larger population of sJIA patients with active
systemic features (Ruperto et al., 2012). In the first trial, 84% of
patients receiving a single injection of canakinumab compared
with only 10% of those receiving placebo achieved an ACR
Pediatric 30 response with no fever (p < 0.001). The frequency
of inactive disease in the canakinumab group was as high as
33% after only 15 days. In the second trial, conducted with a
withdrawal design, 73% of the patients demonstrated at least an
ACR Pediatric 50 response and no fever and 31% had inactive
disease at the end of the open-label phase, after a median of 113
days. In the randomized withdrawal phase, the frequency of
flare was markedly lower in the canakinumab group than in the
placebo group (74% of patients in the canakinumab group had
no flare, vs. 25% in the placebo group; P = 0.003). At the end
of the withdrawal phase, 62% of canakinumab-treated patients
and 34% of patients in the placebo group had inactive disease.
The average corticosteroid dose was reduced from 0.34 to 0.05
mg/kg/day and corticosteroids were discontinued in 33% of
patients. Medication safety was overall good, although infections
were more frequent with canakinumab than with placebo and 7
patients had MAS.
Canakinumab has been approved for the treatment for the
treatment of active sJIA in children aged 2 years and older both
in Europe and in the US.
Rilonacept
The efficacy and safety of the anti-IL-1 soluble decoy receptor
protein, rilonacept, were evaluated in a pilot 3-phase trial
consisting in a 23 months of open-label treatment preceded
by a 4 week, double-blind, placebo-controlled phase. Although
no significant differences in efficacy were observed between
the rilonacept- and placebo-treated patients during the initial
double-blind phase, fever and rash completely resolved by month
3 in all patients during the open-label treatment period and
did not recur. The adapted ACR Pedi 30, 50, and 70 response
rates at 3 months were 78.3, 60.9, and 34.8%, respectively, and
were generally maintained over the study duration. In addition
to declines in high-sensitivity CRP, reductions were seen in the
levels of MRP-8/MRP-14 and D-dimer. In 22 of 23 patients,
prednisone was tapered or discontinued. Treatment was not
associated with serious adverse events (Lovell et al., 2013).
A larger 24 week randomized trial of the same agent in 71
children with active arthritis in ≥2 joints, which incorporated
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a 4 week double-blind placebo phase, found a shorter time
to response in the rilonacept arm than in the placebo arm
(P = 0.007). In a secondary analysis, 57% of the patients in the
rilonacept arm had a response at week 4 compared with 27%
of the patients in the placebo arm (P = 0.016). No statistically
significant association was observed between a poorer response
at week 4 and absence of systemic manifestations or longer
disease duration. However, the median disease duration tended
to shorter among patients who responded at week 4 compared to
those who did not. The medication was generally well-tolerated
(Ilowite et al., 2014).
Thus far, rilonacept has not been approved for use in children
with sJIA.
OPEN ISSUES AND FUTURE OUTLOOK
The advent of biologic agents that specifically inhibit IL-1 has
dramatically improved clinical outcomes for many children with
sJIA and confirmed the pathogenic role of this cytokine in disease
processes. The demonstration of the prominent involvement
of IL-1, together with the lack of HLA associations and
autoantibodies and the strong implication of cells of the innate
immune system, has led to the suggestion that sJIA is a distinct
disease entity, with more similarities with autoinflammatory
syndromes than with classic autoimmune diseases (Masters et al.,
2009; Vastert et al., 2009; Mellins et al., 2011; Martini, 2012b).
However, not all patients respond to IL-1 blockade (Gattorno
et al., 2008; Lequerré et al., 2008; Swart et al., 2010; Quartier
et al., 2011). The varying susceptibility to anti-IL-1 therapy may
be explained by the heterogeneity of sJIA. The aforementioned
analysis of the pattern of response to anakinra identified two
patient subsets, one with dramatic response, similar to that
observed in cryopirin-associated autoinflammatory syndromes,
and the other resistant or with an intermediate response. Patients
responding to anti-IL-1 therapy had fewer affected joints and a
higher neutrophil count (Gattorno et al., 2008). This observation
has led to postulate that the groupwith bright response represents
a separate entity in which autoinflammatory mechanisms play
the leading pathogenetic role, whereas the group with more
severe arthritis may also have autoimmune components (Martini,
2012a). Other investigators have found evidence that anti-IL-
1 treatment may be more effective for systemic features than
for articular manifestations of the disease (Lovell et al., 2013).
However, in the canakinumab study, the response to treatment
of children with polyarthritis was similar to those without
polyarthritis. A differential therapeutic response based on the
presence or absence of systemic features could not be evaluated in
this trial because all children enrolled had ongoing fever (Ruperto
et al., 2012).
The heterogeneous nature of sJIA has been further highlighted
by Shimizu and co-workers (Shimizu et al., 2013), who delineated
two distinct sJIA patient subsets based on their serum IL-6 and
IL-18 levels: an IL-6 dominant and an IL-18 dominant. The IL-
6-dominant subset had a more severe polyarthritis and higher
serum levels of matrix metalloproteinase (MMP-3), whereas
the IL-18-dominant subset was more prone to develop MAS.
Whether the differences in the predominant cytokine expression
or in the susceptibility to anti-cytokine therapies dissect the
spectrum of systemic JIA into clinically or pathogenetically
distinct disease entities, remains to be established.
As noticed above, the tendency for ferritin level to be higher in
responders to anakinra in some series suggests that patients with
more pronounced activation of the monocyte system, which may
predispose them to the progression to overt MAS, may be more
susceptible to benefit from IL-1 inhibition. This hypothesis is in
keeping with the recent reports of the effectiveness of anakinra in
cases of MAS refractory to conventional therapies (Ravelli et al.,
2012).
Another explanation for the inconsistent effectiveness of IL-1
inhibition could be the timing of therapy. Nearly all patients
included in earlier open studies and in randomized clinical
trials had long-standing disease and were still receiving systemic
corticosteroids when treatment with IL-1 blocking agents was
initiated. These characteristics may account for the partial or
absent responses seen in a significant minority of patients. More
favorable outcomes were obtained with the use of IL-blockade
as first-line therapy, particularly in patients with new-onset
disease and not yet exposed to corticosteroids or other DMARDs
(Nigrovic et al., 2011; Vastert et al., 2014). Many patients
achieved inactive disease rapidly and were able to stop anti-IL-1
therapy within 1 year, with sustained remission during follow-up
(Vastert et al., 2014). Of equal importance was the observation
of a significant reduction in the proportion of children who
developed the chronic polyarthritis manifestation of their disease
(Nigrovic et al., 2011).
The differential clinical responses in early vs. late disease,
coupled with data from animal models, have led to theorize a
biphasic model of sJIA, in which the disease begins with a highly
inflammatory febrile phase that, in more than half of the patients,
converts over time to an afebrile phase characterized by chronic
arthritis. The predominance of innate immune mechanisms in
the early systemic stage, as opposed to the involvement of
autoreactive T-cells in the later induction of chronic arthritis,
would explain why antagonism of IL-1 in new-onset disease
is associated with better outcomes than those observed when
this therapy is initiated later in the disease course. Thus, early
treatment with IL-1 inhibitors may take advantage of this
“window of opportunity,” in which disease pathophysiology can
be altered to avoid the occurrence of chronic arthritis (Nigrovic,
2014).
However, although this hypothesis is logical and attractive,
its clinical background should be regarded in the light of some
caveats. Because around 40% of patients with sJIA have a
monocyclic course with spontaneous remission, results of open
studies on patients with early disease may be biased toward
patients destined to a milder course. Conversely, most patients
enrolled in clinical trials had already had years of disease and,
therefore, are unlikely to include patients with a monophasic
course. In addition, the majority of these patients had proven
refractory to other therapies. Thus, the observed different efficacy
of IL-1 blockade between early and established sJIA could simply
reflect the fact that the latter patient subset may be more
challenging to treat. Nevertheless, although the hypothesis of a
window of opportunity is far from proven, it should become
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TABLE 3 | Characteristics of the IL-1 inhibitors used for the treatment of sJIA.
Dosage Route of administration Half-life
Anakinra 1–4mg/kg/day Subcutaneous 4–6 h
Canakinumab ≥2 years: 4mg/kg/dose q 4 weeks Subcutaneous 23–26 days
Maximum dose: 300mg
Rilonacept Starting dose 4.4 mg/kg, then 2.2 mg/kg/week Subcutaneous 1 week
Maximum loading dose: 320mg
Maximum weekly dose: 160 mg/week
the focus of further research into the pathophysiology of sJIA
and, possibly, the objective of further multicenter trials in large
populations, ideally combined with biomarker analyses.
Since there are now three IL-1 inhibitors on the market, the
question arises about which of them is preferable. Not only
they differ in the molecular structure, but the mechanism of
action is slightly different: anakinra blocks both IL-1α and IL-1β,
canakinumab inhibits only IL-1β, and rilonacept binds IL-1α,
IL-1β, and IL-1 receptor antagonist. However, it is still unknown
whether the different biding properties translate into differential
clinical effects (Beukelman, 2014). Anakinra has been the first
agent tested and is, thus, the one for which more experience has
been gained (although it is not registered for the treatment of
sJIA). It has a short half-life of 4–6 h, which is advantageous for
handling a major adverse event and provides a greater flexibility
for the management of a medical emergency like MAS. However,
the need of daily subcutaneous administrations, which are often
associated with injection site reactions, may make it difficult to
conduct therapy over long-term, particularly in younger children
(Lequerré et al., 2008; Quartier et al., 2011). The longer half-
life of canakinumab, which enables its administration every 4
weeks, together with its blockage limited to IL-1β, makes this
medication potentially better accepted and tolerated. Rilonacept
could offer an alternative with its circulating half-life of 8.6 days,
in contrast to the long biologic activity of canakinumab (236
days), which could be a disadvantage in the setting of a serious
toxic effect. Importantly, significant responses to canakinumab
and rilonacept were seen in many patients who had previously
been treated with anakinra, which suggests that failure of one
anti-IL-1 therapy does not necessarily preclude use of another
(Lovell et al., 2013). Last but not least, the issue of cost may have a
major impact on the choice of a particular molecule. The dosage,
route of administration and half-life of the IL-1 inhibitors used in
the management of sJIA is reported in Table 3.
Overall, all anti-IL-1 agents have proven safe and
well-tolerated. However, concerns have been raised regarding
the risk of infection, neutropenia, and liver dysfunction (Canna
et al., 2009; Sandborg and Mellins, 2012; Buckland, 2013).
Furthermore, several instances of MAS during treatment with
IL-1 inhibitors, some of which with a fatal outcome, have been
seen in clinical practice, randomized controlled trials, and
post-marketing experience (Grom and Mellins, 2010; Ruperto
et al., 2012). The same phenomenon was reported during
treatment with the IL-6 blocker tocilizumab (De Benedetti
et al., 2012; Yokota et al., 2012). As discussed elsewhere, the
occurrence of MAS during treatment with medications that
inhibit proinflammatory cytokines implicated in its pathogenesis
is a paradoxical phenomenon. Possible explanations include
the increased rate of infections (which, in turn, may trigger
MAS) associated with biologic therapies or the induction of
an imbalance between up- and down-regulation of the various
molecules that are part of the cytokine network (Ravelli et al.,
2012; Minoia et al., 2014). However, these episodes of MAS often
abated after increasing the dose of biologic medications, which
suggests a lack of causality and a real associative relationship in
only a few instances.
Treatment targeting another cytokine implicated in the
pathogenesis of sJIA, such as the IL-6 blocker tocilizumab, has
also demonstrated efficacy in clinical trials (De Benedetti et al.,
2012; Yokota et al., 2012). So far, however, there are no clinical
data that allow either to compare the effectiveness and safety of
IL-1 and IL-6 antagonists or to establish their relative indications
in sJIA.
Additional investigations are needed to define the exact role of
the currently available agents in the management of sJIA. Future
studies will likely optimize the care of children with sJIA and
further elucidate the disease pathogenesis.
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